Similarly, viral replication SRPK1/2 inhibitors that have been shown to reduce SAR-SCoV-2 continue to be developed as potential cancer drugs, e.g., feasible strategies to interfere with SARS-CoV-2 replication and transmission include use of the FDA-approved kinase inhibitor alectinib, which strongly reacts with SRPK1 and inhibits SRPK1; the reuse of SRPK1/2 or GSK-3 inhibitors; or the development of new inhibitors [180, 185]. The gene discussed is SRPK1; the disease is cancer.